# OnCo record paper-codebreak-300-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-codebreak-300-nejm-2023" ;
  schema:name "CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer"@en ;
  schema:description "Combining a KRAS G12C inhibitor with an EGFR antibody produced responses in about a quarter of patients with heavily pretreated KRAS G12C bowel cancer, versus none with standard chemotherapy, and more than doubled the time to progression."@en ;
  schema:url <https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2308795>, <https://clinicaltrials.gov/study/NCT05198934>, <https://pubmed.ncbi.nlm.nih.gov/37870968/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2308795> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Fakih MG, Salvatore L, Esaki T, et al." ;
  onco:related <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/>, <https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/kras-g12c-colorectal/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/regorafenib/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/codebreak-300/> ;
  onco:people <https://onco.cc/people/kim-tae-won/>, <https://onco.cc/people/david-cunningham/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-dose-optimisation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .